Full Text
Secukinumab As A More Efficient Alternative For The Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis Versus Adalimumab And Golimumab From A Colombian Perspective

Abstract

Authors

A Patino E Karpf

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×